Quantinno Capital Management LP Has $47.20 Million Stock Position in Insulet Corporation $PODD

Quantinno Capital Management LP increased its position in shares of Insulet Corporation (NASDAQ:PODD) by 35.1% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 224,951 shares of the medical instruments supplier’s stock after buying an additional 58,388 shares during the quarter. Quantinno Capital Management LP’s holdings in Insulet were worth $47,204,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Mitsubishi UFJ Trust & Banking Corp lifted its position in Insulet by 26.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after acquiring an additional 9,206 shares during the last quarter. Aberdeen Group plc grew its position in shares of Insulet by 45.6% in the fourth quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock valued at $64,076,000 after purchasing an additional 70,607 shares during the last quarter. Asset Management One Co. Ltd. increased its stake in shares of Insulet by 99.5% in the fourth quarter. Asset Management One Co. Ltd. now owns 76,594 shares of the medical instruments supplier’s stock worth $21,948,000 after purchasing an additional 38,193 shares during the period. OP Asset Management Ltd bought a new position in shares of Insulet in the first quarter worth about $1,513,000. Finally, Strs Ohio lifted its position in shares of Insulet by 36.0% during the 4th quarter. Strs Ohio now owns 22,680 shares of the medical instruments supplier’s stock worth $6,447,000 after purchasing an additional 6,003 shares during the last quarter.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer bought 2,790 shares of Insulet stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This trade represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PODD has been the topic of a number of research analyst reports. Sanford C. Bernstein lowered their target price on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Bank of America cut their price target on Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Raymond James Financial set a $216.00 price objective on Insulet in a research report on Monday, June 8th. JPMorgan Chase & Co. dropped their target price on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating on the stock in a research report on Thursday, May 7th. Finally, Evercore set a $180.00 target price on shares of Insulet in a research report on Monday, July 6th. Twenty-one investment analysts have rated the stock with a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and a consensus price target of $233.38.

Insulet Trading Up 1.9%

Insulet stock opened at $170.62 on Thursday. The business has a 50 day moving average price of $154.87 and a two-hundred day moving average price of $199.34. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The stock has a market cap of $11.82 billion, a price-to-earnings ratio of 39.68, a price-to-earnings-growth ratio of 1.17 and a beta of 1.11. Insulet Corporation has a 12 month low of $138.79 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the company earned $1.02 EPS. The company’s quarterly revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts forecast that Insulet Corporation will post 6.45 EPS for the current year.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Neutral Sentiment: UBS initiated coverage of Insulet with a “neutral” rating and a $174 price target, implying modest upside from the referenced price. The rating suggests UBS sees a balanced risk-reward profile rather than a strong near-term catalyst. Benzinga reference
• Neutral Sentiment: Multiple law firms reminded investors of an August 31, 2026 deadline to seek lead-plaintiff status in a securities-fraud lawsuit against Insulet and certain executives. The notices reference slightly different class periods, generally covering purchases from February or May 2025 through May 26, 2026. Rosen Law Firm article
• Negative Sentiment: The complaints reportedly allege that defective cannula manufacturing caused insulin under-delivery in millions of Omnipod devices and that Insulet failed to disclose manufacturing deficiencies and product-safety risks. One notice also alleges that executive Eric Benjamin sold approximately $3.7 million of Insulet stock before two medical-device corrections. These are allegations, not established findings, but the litigation could increase costs and intensify scrutiny of Insulet’s quality controls and disclosures. SueWallSt shareholder alert

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.